Sharada has spent the last decade building global IP freedom to operate strategies to support biosimilar launches, such as natalizumab, denosumab, adalimumab, and rituximab. She started her career in the US with the patent litigation group at Proskauer Rose, participating in several ITC litigations in addition to her district court docket. In 2012, she moved to Boehringer Ingelheim shifting her career to the then-new and exciting biosimilars market. There she helped build strategies for most of the first wave biosimilar, in addition to advising her client how to prepare for global biosimilar litigation. More recently, she leads the biosimilar patent team at Sandoz, a global leader in biosimilars, and is responsible for advising on freedom-to-operate, portfolio strategy, financial risk assessment, and settlement negotiations.